Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Core Insights - The New England Journal of Medicine published results from Novo Nordisk's phase 3 REDEFINE 1 trial, demonstrating the efficacy and safety of CagriSema for weight loss in adults with obesity or overweight and weight-related medical complications without diabetes [1][2] - CagriSema achieved significant weight loss of 22.7% at 68 weeks compared to 2.3% in the placebo group, with 50.7% of participants reaching a BMI below 30 kg/m² [2][3] Company Overview - Novo Nordisk is a leading global healthcare company focused on chronic diseases, particularly diabetes, and is pioneering scientific breakthroughs in obesity treatment [12] - The company has initiated multiple clinical trials, including REDEFINE 11, to further investigate the efficacy and safety of CagriSema [7][10] Clinical Trial Details - The REDEFINE 1 trial involved 3,417 adults and was a double-blind, placebo-controlled study lasting 68 weeks [9] - The REDEFINE 2 trial, which included 1,206 adults with type 2 diabetes, also showed significant weight loss results, with 97.6% of participants losing at least 5% of their body weight [5][6] Efficacy and Safety Results - In REDEFINE 1, 40.4% of participants achieved a body weight reduction of ≥25%, and 23.1% lost ≥30% [3] - Adverse events were primarily gastrointestinal, with low discontinuation rates of 6% for CagriSema compared to 3.7% for placebo in REDEFINE 1 [4] Future Directions - The REDEFINE clinical program will continue to assess CagriSema's efficacy and safety, with ongoing trials aimed at exploring its weight loss potential [7][10]